

Application for Quotation of Additional Securities

File Reference:

I:\Issuers\Frms\website forms\documents 2016\issuers\NSX Quotation of Additional Securities.doc

Table of Contents

INTRODUCTION	2
NEW ISSUE ANNOUNCEMENT, APPLICATION FOR QUOTATION OF ADDITIONAL SECURITIES AND AGREEMENT	3
PART 1 - ALL ISSUES	3
PART 2 - BONUS ISSUE OR PRO RATA ISSUE	5
PART 3 - QUOTATION OF SECURITIES	7
ADDITIONAL SECURITIES FORMING A NEW CLASS OF SECURITIES	7
QUOTATION AGREEMENT	9

Introduction

To ensure the efficient processing of this form by NSX, please:

1. Adhere to the suggested number of the annexures required by this form.
2. Complete **all** statements and questions in this form. (NSX can provide an electronic version of this form on request).

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to NSX as soon as available. Information and documents given to NSX become NSX's property and may be made public.

Introduced 11 March 2004. Revised 7 March 2016.

Name of entity

Endless Solar Corporation Limited

ABN/ACN

122 708 061

We (the entity) give NSX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|---|---|
| 1 | Class of securities issued or to be issued | Options |
| 2 | Number of securities issued or to be issued (if known) or maximum number which may be issued | 3,000,000 Options over ESCLV Shares at 12 cents per share and exercisable any time up to 20 June 2027. |
| 3 | Principal terms of the securities (eg, if options, exercise price and expiry date; if partly paid securities, the amount outstanding and due dates for payment; if convertible securities, the conversion price and dates for conversion) | ESC to grant to Kevin Mooney 3,000,000 Options over ESCLV Shares at 12 cents per share and exercisable any time up to 20 June 2027. |
| 4 | <p>Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | Yes |

5	Issue price or consideration	\$0.12 Options	
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	New Director Issue (Kevin Mooney)	
7	Dates of entering securities into uncertificated holdings or despatch of certificates	To be issued 27 May 2022	
8	Number and class of all securities quoted on NSX (including the securities in clause 2 if applicable)	Number	Class
		79,926,022	Fully Paid Ordinary
9	Number and class of all securities not quoted on NSX (including the securities in clause 2 if applicable)	Number	Class
		6,000,000	ESCLV Options at \$0.12 expires on 20 th June 2027
		15,324,050	ESCLV Shares to ESCCN at \$0.10 expires on 22 nd Oct 2025
		6,200,000	ESCLV Options to ESCOH at \$0.10 expires on 22 nd October 2025
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)		

Part 2 - Bonus issue or pro rata issue

- | | | |
|----|--|--|
| 11 | Is security holder approval required? | |
| 12 | Is the issue renounceable or non-renounceable? | |
| 13 | Ratio in which the securities will be offered | |
| 14 | Class of securities to which the offer relates | |
| 15 | Record date to determine entitlements | |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | |
| 17 | Policy for deciding entitlements in relation to fractions | |
| 18 | Names of countries in which the entity has security holders who will not be sent new issue documents

Note: Security holders must be told how their entitlements are to be dealt with. | |
| 19 | Closing date for receipt of acceptances or renunciations | |
| 20 | Names of any underwriters | |
| 21 | Amount of any underwriting fee or commission | |
| 22 | Names of any brokers to the issue | |
| 23 | Fee or commission payable to the broker to the issue | |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders | |

-

You need only complete this section if you are applying for quotation of securities

(a) ☒ Securities described in Part 1

(b)  All other securities

Entities that have ticked box 34(a)

Tick to indicate you are providing the information or documents

36  If the securities are equity securities, a distribution schedule of the additional securities setting out the number of holders in the categories

- 1 - 1,000
- 1,001 - 5,000
- 5,001 - 10,000
- 10,001 - 100,000
- 100,001 and over

37 ☐ A copy of any trust deed for the additional securities

Entities that have ticked box 34(b)

--

--

Patient Information	
First Name	
Last Name	
Address	
City	
State	
Zip	
Phone	
Age	
Gender	
Occupation	
Insurance	
Referral	
History of Present Illness	
Onset	
Duration	
Frequency	
Severity	
Associated symptoms	
Exacerbating factors	
Relieving factors	
Past medical history	
Surgical history	
Medication history	
Allergies	
Social history	
Family history	
Review of Systems	
General	
Cardiovascular	
Respiratory	
Gastrointestinal	
Genitourinary	
Neurological	
Musculoskeletal	
Dermatological	
Endocrine	
Hematological	
Immunological	
Psychological	
Social	
Physical Examination	
Vital signs	
General appearance	
Head and neck	
Chest	
Abdomen	
Genitourinary	
Neurological	
Musculoskeletal	
Dermatological	
Laboratory and Diagnostic Tests	
Blood tests	
Urine tests	
Imaging studies	
Special studies	
Treatment and Management	
Medications	
Surgery	
Physical therapy	
Counseling	
Follow-up	

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

--

(if issued upon conversion of another security, clearly identify that other security)

Number	Class

Quotation agreement

1 Quotation of our additional securities is in NSX's absolute discretion. NSX may quote the securities on any conditions it decides.

2 We warrant the following to NSX.

- The issue of the securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those securities should not be granted quotation.
- An offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any securities to be quoted and that no-one has any right to return any securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the securities to be quoted, it has been provided at the time that we request that the securities be quoted.
- If we are a trust, we warrant that no person has the right to return the securities to be quoted under section 1019B of the Corporations Act at the time that we request that the securities be quoted.

3 We will indemnify NSX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give NSX the information and documents required by this form. If any information or document not available now, will give it to NSX before quotation of the securities begins. We acknowledge that NSX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here: Date:27 June 2022.....
(Director)

Print name:David Craig